Lonza Group Ltd
LO3A
Company Profile
Business description
Lonza Group is a leading contract development and manufacturing organization operating through three main segments: integrated biologics, advanced synthesis, and specialized modalities. It generates revenue primarily through long-term supply agreements with biopharmaceutical customers. The company provides comprehensive services spanning the entire product lifecycle, from early-stage drug development to large-scale commercial supply. Its diverse client base includes global pharmaceutical and biotechnology companies, academic institutions, and research organizations.
Contact
Muenchensteinerstrasse 38
Basel4002
CHET: +41 613168111
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
20,141
Stocks News & Analysis
stocks
Weight loss drugs not an existential threat to undervalued ASX share
A durable growth story despite GLP-1 headwinds.
stocks
Tesla: valuation is key consideration in merger talks with SpaceX
We see regulatory risk from both the US and Chinese governments.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,968.80 | 42.20 | 0.47% |
| CAC 40 | 7,883.25 | 35.93 | 0.46% |
| DAX 40 | 25,516.02 | 105.18 | 0.41% |
| Dow JONES (US) | 52,267.70 | 93.88 | -0.18% |
| FTSE 100 | 10,668.83 | 98.50 | -0.91% |
| HKSE | 23,041.32 | 170.49 | -0.73% |
| NASDAQ | 26,267.35 | 97.97 | 0.37% |
| Nikkei 225 | 63,268.37 | 1,078.72 | 1.73% |
| NZX 50 Index | 13,680.27 | 53.66 | -0.39% |
| S&P 500 | 7,683.47 | 6.70 | 0.09% |
| S&P/ASX 200 | 8,850.10 | 40.20 | 0.46% |
| SSE Composite Index | 3,648.30 | 49.22 | -1.33% |